Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
7 "Seung Eun Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Complications
Glycemic Control and Retinal Microvascular Changes in Type 2 Diabetes Mellitus Patients without Clinical Retinopathy
Kangmin Lee, Ga Hye Lee, Seung Eun Lee, Jee Myung Yang, Kunho Bae
Received May 15, 2023  Accepted December 15, 2023  Published online March 13, 2024  
DOI: https://doi.org/10.4093/dmj.2023.0149    [Epub ahead of print]
  • 761 View
  • 40 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To investigate the association of glycemic control and retinal microvascular changes in patients with type 2 diabetes mellitus (T2DM) without diabetic retinopathy (DR).
Methods
This retrospective, observational, cohort study included patients with T2DM without DR. The patients were categorized into intensive control (IC; mean glycosylated hemoglobin [HbA1c] ≤7.0%) and moderate control (MC; mean HbA1c >7.0%) groups. Optical coherence tomography (OCT) and swept-source OCT angiography (OCTA) image parameters were compared between three groups, including healthy controls.
Results
In total, 259 eyes of 259 participants (88 IC, 81 MC, and 90 controls) were included. The foveal avascular zone area was significantly larger in the MC group than IC and control groups (all P<0.05). The IC group had lower vessel density in the superficial retinal layer and deep retinal layer than the controls (all P<0.05). The choriocapillaris (CC) flow deficit (FD) was significantly greater in the MC group than in the IC and control groups (18.2%, 16.7%, and 14.2%, respectively; all P<0.01). In multivariate regression analysis, CC-FD was associated with the mean HbA1c level (P=0.008). There were no significant differences in OCT parameters among the groups.
Conclusion
OCTA revealed that early CC impairment is associated with HbA1c levels; the CC changes precede clinically apparent DR. The OCTA parameters differed among the groups according to the degree of glycemic control. Our results suggest that microvascular changes precede DR and are closely related to glycemic control.
Cardiovascular Risk/Epidemiology
Two-Year Changes in Diabetic Kidney Disease Phenotype and the Risk of Heart Failure: A Nationwide Population-Based Study in Korea
Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
Diabetes Metab J. 2023;47(4):523-534.   Published online April 25, 2023
DOI: https://doi.org/10.4093/dmj.2022.0096
  • 1,821 View
  • 100 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Diabetic kidney disease (DKD) is a risk factor for hospitalization for heart failure (HHF). DKD could be classified into four phenotypes by estimated glomerular filtration rate (eGFR, normal vs. low) and proteinuria (PU, negative vs. positive). Also, the phenotype often changes dynamically. This study examined HHF risk according to the DKD phenotype changes across 2-year assessments.
Methods
The study included 1,343,116 patients with type 2 diabetes mellitus (T2DM) from the Korean National Health Insurance Service database after excluding a very high-risk phenotype (eGFR <30 mL/min/1.73 m2) at baseline, who underwent two cycles of medical checkups between 2009 and 2014. From the baseline and 2-year eGFR and PU results, participants were divided into 10 DKD phenotypic change categories.
Results
During an average of 6.5 years of follow-up, 7,874 subjects developed HHF. The cumulative incidence of HHF from index date was highest in the eGFRlowPU– phenotype, followed by eGFRnorPU+ and eGFRnorPU. Changes in DKD phenotype differently affect HHF risk. When the persistent eGFRnorPU category was the reference, hazard ratios for HHF were 3.10 (95% confidence interval [CI], 2.73 to 3.52) in persistent eGFRnorPU+ and 1.86 (95% CI, 1.73 to 1.99) in persistent eGFRlowPU. Among altered phenotypes, the category converted to eGFRlowPU+ showed the highest risk. In the normal eGFR category at the second examination, those who converted from PU to PU+ showed a higher risk of HHF than those who converted from PU+ to PU.
Conclusion
Changes in DKD phenotype, particularly with the presence of PU, are more likely to reflect the risk of HHF, compared with DKD phenotype based on a single time point in patients with T2DM.
Cardiovascular Risk/Epidemiology
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
Seung Eun Lee, Hyewon Nam, Han Seok Choi, Hoseob Kim, Dae-Sung Kyoung, Kyoung-Ah Kim
Diabetes Metab J. 2022;46(4):567-577.   Published online February 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0160
  • 5,629 View
  • 361 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk. Additionally, meta-analysis showed SGLT-2i potentially had an adverse effect on stroke risk. Contrarily, pioglitazone, a type of thiazolidinedione (TZD), has been shown to reduce recurrent stroke risk. Thus, we aimed to compare the effect of SGLT-2i and TZD on the risk of stroke in type 2 diabetes mellitus (T2DM) patients.
Methods
Using the Korean National Health Insurance Service data, we compared a 1:1 propensity score-matched cohort of patients who used SGLT-2i or TZD from January 2014 to December 2018. The primary outcome was stroke. The secondary outcomes were myocardial infarction (MI), cardiovascular death, 3-point MACE, and heart failure (HF).
Results
After propensity-matching, each group included 56,794 patients. Baseline characteristics were well balanced. During the follow-up, 862 patients were newly hospitalized for stroke. The incidence rate of stroke was 4.11 and 4.22 per 1,000 person-years for the TZD and SGLT-2i groups respectively. The hazard ratio (HR) of stroke was 1.054 (95% confidence interval [CI], 0.904 to 1.229) in the SGLT-2i group compared to the TZD group. There was no difference in the risk of MI, cardiovascular death, 3-point MACE between groups. Hospitalization for HF was significantly decreased in SGLT-2i-treated patients (HR, 0.645; 95% CI, 0.466 to 0.893). Results were consistent regardless of prior cardiovascular disease.
Conclusion
In this real-world data, the risk of stroke was comparable in T2DM patients treated with SGLT-2i or TZD.

Citations

Citations to this article as recorded by  
  • Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
    André J. Scheen
    Diabetes Epidemiology and Management.2024; 13: 100179.     CrossRef
  • Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
    André J. Scheen
    Diabetes & Metabolism.2023; 49(5): 101474.     CrossRef
Metabolic Risk/Epidemiology
Insulin Resistance Increases Serum Immunoglobulin E Sensitization in Premenopausal Women
Seung Eun Lee, Ji Yeon Baek, Kyungdo Han, Eun Hee Koh
Diabetes Metab J. 2021;45(2):175-182.   Published online April 14, 2020
DOI: https://doi.org/10.4093/dmj.2019.0150
  • 6,341 View
  • 123 Download
  • 2 Web of Science
  • 2 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFPubReader   ePub   
Background

Although studies have shown that obesity is associated with aeroallergen sensitization (atopy), controversy still exists. We aimed to investigate the association between metabolic status, obesity, and atopy stratified by sex and menopausal status.

Methods

A total of 1,700 adults from the 2010 Korean National Health and Nutrition Examination Survey were classified into metabolically healthy nonobese (MHNO), metabolically unhealthy nonobese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO) by body mass index and insulin resistance. Atopy was defined as a positive response to at least one aeroallergen. Multiple regression analysis was used to evaluate the risk of immunoglobulin E (IgE) elevation or atopy in relation to the degree of metabolic abnormality and obesity.

Results

In premenopausal women, total IgE was positively correlated with obesity and insulin resistance. MUNO participants had a higher risk of having elevated total IgE compared to MHNO participants (odds ratio [OR], 2.271; 95% confidence interval [CI], 1.201 to 4.294), while MHO participants did not show a significant difference (OR, 1.435; 95% CI, 0.656 to 3.137) in premenopausal women. MUNO, but not MHO was also associated with atopy (OR, 2.157; 95% CI, 1.284 to 3.625). In men and postmenopausal women, there was no significant difference between metabolic status, obesity, and atopy among groups.

Conclusion

Increased insulin resistance is associated with total IgE and atopy in premenopausal women but not in postmenopausal women or men.

Citations

Citations to this article as recorded by  
  • Association of serum total IgE and allergen-specific IgE with insulin resistance in adolescents: an analysis of the NHANES database
    Yaping Liu, Xiaoxia Wang, Yong Liu
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Is There a Relationship between Insulin Resistance and Eosinophil, Inflammatory Parameters Neutrophil to lymphocyte ratio, C-Reactive Protein Values?
    Meltem YİĞİT, Özgür OLUKMAN
    Medical Records.2024; 6(1): 32.     CrossRef
Sulwon Lecture 2018
Pathophysiology
Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation
Chang-Yun Woo, Jung Eun Jang, Seung Eun Lee, Eun Hee Koh, Ki-Up Lee
Diabetes Metab J. 2019;43(3):247-256.   Published online March 27, 2019
DOI: https://doi.org/10.4093/dmj.2018.0221
  • 8,774 View
  • 261 Download
  • 70 Web of Science
  • 71 Crossref
AbstractAbstract PDFPubReader   

Adipose tissue inflammation is considered a major contributing factor in the development of obesity-associated insulin resistance and cardiovascular diseases. However, the cause of adipose tissue inflammation is presently unclear. The role of mitochondria in white adipocytes has long been neglected because of their low abundance. However, recent evidence suggests that mitochondria are essential for maintaining metabolic homeostasis in white adipocytes. In a series of recent studies, we found that mitochondrial function in white adipocytes is essential to the synthesis of adiponectin, which is the most abundant adipokine synthesized from adipocytes, with many favorable effects on metabolism, including improvement of insulin sensitivity and reduction of atherosclerotic processes and systemic inflammation. From these results, we propose a new hypothesis that mitochondrial dysfunction in adipocytes is a primary cause of adipose tissue inflammation and compared this hypothesis with a prevailing concept that “adipose tissue hypoxia” may underlie adipose tissue dysfunction in obesity. Recent studies have emphasized the role of the mitochondrial quality control mechanism in maintaining mitochondrial function. Future studies are warranted to test whether an inadequate mitochondrial quality control mechanism is responsible for mitochondrial dysfunction in adipocytes and adipose tissue inflammation.

Citations

Citations to this article as recorded by  
  • Prolonged Endurance Exercise Increases Macrophage Content and Mitochondrial Respiration in Adipose Tissue in Trained Men
    Ronni Eg Sahl, Ioanna Patsi, Mikkel Thunestvedt Hansen, Tue Rømer, Jacob Frandsen, Hanne Kruuse Rasmusen, Arthur Ingersen, Steen Seier Poulsen, Flemming Dela, Steen Larsen, Jørn Wulff Helge
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e799.     CrossRef
  • The Role of Ion-Transporting Proteins in Human Disease
    Yoshinori Marunaka
    International Journal of Molecular Sciences.2024; 25(3): 1726.     CrossRef
  • The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
    Preethi Chandrasekaran, Ralf Weiskirchen
    International Journal of Molecular Sciences.2024; 25(3): 1882.     CrossRef
  • The Metabolic Syndrome, a Human Disease
    Marià Alemany
    International Journal of Molecular Sciences.2024; 25(4): 2251.     CrossRef
  • Inflammation‐mediated metabolic regulation in adipose tissue
    Shujie Xu, Feng Lu, Jianhua Gao, Yi Yuan
    Obesity Reviews.2024;[Epub]     CrossRef
  • Sleeve Gastrectomy Reduces Oxidative Stress and Reverses Mitochondrial Dysfunction Associated with Metabolic Syndrome
    Micaela M. Rossi, Franco J. Signorini, Tomas A. Castillo, María P. Scribano Parada, Federico Moser, Maria dC Baez
    Obesity Surgery.2024; 34(6): 2042.     CrossRef
  • The relationships between high-fat diet and metabolic syndrome: Potential mechanisms
    Chao Tang, Yuxin Wang, Zeyu Xu, Dan Chen, Jingguo Xu, Duo Yang, Li Zhang, Jun Liu, Juan Kan
    Food Bioscience.2024; 59: 104261.     CrossRef
  • Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence
    Luigi Barrea, Massimiliano Caprio, Mikiko Watanabe, Giuseppe Cammarata, Alessandra Feraco, Giovanna Muscogiuri, Ludovica Verde, Annamaria Colao, Silvia Savastano
    Critical Reviews in Food Science and Nutrition.2023; 63(26): 8320.     CrossRef
  • The emergent role of mitochondrial RNA modifications in metabolic alterations
    Hatim Boughanem, Yvonne Böttcher, João Tomé‐Carneiro, María‐Carmen López de las Hazas, Alberto Dávalos, Akin Cayir, Manuel Macias‐González
    WIREs RNA.2023;[Epub]     CrossRef
  • Age‐associated adipose tissue inflammation promotes monocyte chemotaxis and enhances atherosclerosis
    Jianrui Song, Diana Farris, Paola Ariza, Smriti Moorjani, Mita Varghese, Muriel Blin, Judy Chen, Daniel Tyrrell, Min Zhang, Kanakadurga Singer, Morgan Salmon, Daniel R. Goldstein
    Aging Cell.2023;[Epub]     CrossRef
  • Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
    Harold Edward Bays, Shagun Bindlish, Tiffany Lowe Clayton
    Obesity Pillars.2023; 5: 100056.     CrossRef
  • A role of STING signaling in obesity-induced lung inflammation
    Yong Qi, Zhuhua Wu, Dan Chen, Li Zhu, Yunlei Yang
    International Journal of Obesity.2023; 47(4): 325.     CrossRef
  • Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction
    Alina Kuryłowicz
    Biomedicines.2023; 11(3): 690.     CrossRef
  • White Adipose Tissue Dysfunction: Pathophysiology and Emergent Measurements
    Natalia Santillana, Camila Astudillo-Guerrero, Amanda D’Espessailles, Gonzalo Cruz
    Nutrients.2023; 15(7): 1722.     CrossRef
  • Pleiotropic and multi-systemic actions of physical exercise on PGC-1α signaling during the aging process
    Ivo Vieira de Sousa Neto, Ana Paula Pinto, Vitor Rosetto Muñoz, Rita de Cássia Marqueti, José Rodrigo Pauli, Eduardo Rochete Ropelle, Adelino Sanchez Ramos da Silva
    Ageing Research Reviews.2023; 87: 101935.     CrossRef
  • The impact of metabolic endotoxaemia on the browning process in human adipocytes
    Farah Omran, Alice M. Murphy, Awais Z. Younis, Ioannis Kyrou, Jana Vrbikova, Vojtech Hainer, Petra Sramkova, Martin Fried, Graham Ball, Gyanendra Tripathi, Sudhesh Kumar, Philip G. McTernan, Mark Christian
    BMC Medicine.2023;[Epub]     CrossRef
  • Molecular Mechanisms of Obesity-Induced Development of Insulin Resistance and Promotion of Amyloid-β Accumulation: Dietary Therapy Using Weak Organic Acids via Improvement of Lowered Interstitial Fluid pH
    Yoshinori Marunaka
    Biomolecules.2023; 13(5): 779.     CrossRef
  • From Obesity-Induced Low-Grade Inflammation to Lipotoxicity and Mitochondrial Dysfunction: Altered Multi-Crosstalk between Adipose Tissue and Metabolically Active Organs
    Gina Cavaliere, Fabiano Cimmino, Giovanna Trinchese, Angela Catapano, Lidia Petrella, Margherita D’Angelo, Lucio Lucchin, Maria Pina Mollica
    Antioxidants.2023; 12(6): 1172.     CrossRef
  • Receptor for the Advanced Glycation End Products (RAGE) Pathway in Adipose Tissue Metabolism
    Klaudia Gutowska, Krzysztof Czajkowski, Alina Kuryłowicz
    International Journal of Molecular Sciences.2023; 24(13): 10982.     CrossRef
  • Aerobic and Resistance Training Attenuate Differently Knee Joint Damage Caused by a High-Fat–High-Sucrose Diet in a Rat Model
    Nada Abughazaleh, Kevin Boldt, Jaqueline Lourdes Rios, Stela Marcia Mattiello, Kelsey H. Collins, Ruth-Anne Seerattan, Walter Herzog
    CARTILAGE.2023;[Epub]     CrossRef
  • Exercise mitigates age-related metabolic diseases by improving mitochondrial dysfunction
    Dandan Jia, Zhenjun Tian, Ru Wang
    Ageing Research Reviews.2023; 91: 102087.     CrossRef
  • Mitochondrial dynamics and metabolism across skin cells: implications for skin homeostasis and aging
    Ines Martic, Federica Papaccio, Barbara Bellei, Maria Cavinato
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Diabetes Mellitus, Energy Metabolism, and COVID-19
    Caterina Conte, Elisa Cipponeri, Michael Roden
    Endocrine Reviews.2023;[Epub]     CrossRef
  • Influence of Breastfeeding on the State of Meta-Inflammation in Obesity—A Narrative Review
    Dominika Mazur, Małgorzata Satora, Anna K. Rekowska, Zuzanna Kabała, Aleksandra Łomża, Żaneta Kimber-Trojnar, Bożena Leszczyńska-Gorzelak
    Current Issues in Molecular Biology.2023; 45(11): 9003.     CrossRef
  • AGER-1 Long Non-Coding RNA Levels Correlate with the Expression of the Advanced Glycosylation End-Product Receptor, a Regulator of the Inflammatory Response in Visceral Adipose Tissue of Women with Obesity and Type 2 Diabetes Mellitus
    Klaudia Gutowska, Krzysztof Koźniewski, Michał Wąsowski, Marta Izabela Jonas, Zbigniew Bartoszewicz, Wojciech Lisik, Maurycy Jonas, Artur Binda, Paweł Jaworski, Wiesław Tarnowski, Bartłomiej Noszczyk, Monika Puzianowska-Kuźnicka, Krzysztof Czajkowski, Ali
    International Journal of Molecular Sciences.2023; 24(24): 17447.     CrossRef
  • Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis
    Cong Liu, Milena Schönke, Enchen Zhou, Zhuang Li, Sander Kooijman, Mariëtte R Boon, Mikael Larsson, Kristina Wallenius, Niek Dekker, Louise Barlind, Xiao-Rong Peng, Yanan Wang, Patrick C N Rensen
    Cardiovascular Research.2022; 118(2): 489.     CrossRef
  • Obesity-Related Adipose Tissue Remodeling in the Light of Extracellular Mitochondria Transfer
    Simon Lecoutre, Karine Clément, Isabelle Dugail
    International Journal of Molecular Sciences.2022; 23(2): 632.     CrossRef
  • IL-4 polarized human macrophage exosomes control cardiometabolic inflammation and diabetes in obesity
    Tuan Anh Phu, Martin Ng, Ngan K. Vu, Laura Bouchareychas, Robert L. Raffai
    Molecular Therapy.2022; 30(6): 2274.     CrossRef
  • Insulin-inducible THRSP maintains mitochondrial function and regulates sphingolipid metabolism in human adipocytes
    Maria A. Ahonen, Marcus Höring, Van Dien Nguyen, Sami Qadri, Juuso H. Taskinen, Meghana Nagaraj, Martin Wabitsch, Pamela Fischer-Posovszky, You Zhou, Gerhard Liebisch, P. A. Nidhina Haridas, Hannele Yki-Järvinen, Vesa M. Olkkonen
    Molecular Medicine.2022;[Epub]     CrossRef
  • Modulation of adipose inflammation by cellular retinoic acid-binding protein 1
    Chin-Wen Wei, Jennifer Nhieu, Yu-Lung Lin, Li-Na Wei
    International Journal of Obesity.2022; 46(10): 1759.     CrossRef
  • The Role of Adipokines in Pancreatic Cancer
    Qi Wang, Huizhi Wang, Yuntao Ding, Mengtian Wan, Min Xu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Epigenetic Reprogramming of the Inflammatory Response in Obesity and Type 2 Diabetes
    Federica Zatterale, Gregory Alexander Raciti, Immacolata Prevenzano, Alessia Leone, Michele Campitelli, Veronica De Rosa, Francesco Beguinot, Luca Parrillo
    Biomolecules.2022; 12(7): 982.     CrossRef
  • Cellular Metabolism and Bioenergetic Function in Human Fibroblasts and Preadipocytes of Type 2 Familial Partial Lipodystrophy
    Cristina Algieri, Chiara Bernardini, Fabiana Trombetti, Elisa Schena, Augusta Zannoni, Monica Forni, Salvatore Nesci
    International Journal of Molecular Sciences.2022; 23(15): 8659.     CrossRef
  • Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease
    Ioan-Andrei Iliuta, Xuewen Song, Lauren Pickel, Amirreza Haghighi, Ravi Retnakaran, James Scholey, Hoon-Ki Sung, Gregory R. Steinberg, York Pei
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • Hypoxia as a Double-Edged Sword to Combat Obesity and Comorbidities
    Ruwen Wang, Qin Sun, Xianmin Wu, Yiyin Zhang, Xiaorui Xing, Kaiqing Lin, Yue Feng, Mingqi Wang, Yibing Wang, Ru Wang
    Cells.2022; 11(23): 3735.     CrossRef
  • Macrophage and Adipocyte Mitochondrial Dysfunction in Obesity-Induced Metabolic Diseases
    Liwen Wang, Jie Hu, Haiyan Zhou
    The World Journal of Men's Health.2021; 39(4): 606.     CrossRef
  • ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota
    Sup Kim, June-Young Lee, Seul Gi Shin, Jin Kyung Kim, Prashanta Silwal, Young Jae Kim, Na-Ri Shin, Pil Soo Kim, Minho Won, Sang-Hee Lee, Soo Yeon Kim, Miwa Sasai, Masahiro Yamamoto, Jin-Man Kim, Jin-Woo Bae, Eun-Kyeong Jo
    Autophagy.2021; 17(10): 2856.     CrossRef
  • GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH
    Kook Hwan Kim, Myung-Shik Lee
    Biochimica et Biophysica Acta (BBA) - General Subjects.2021; 1865(3): 129834.     CrossRef
  • The Influence of Obesity and Associated Fatty Acids on Placental Inflammation
    Alison J. Eastman, Rebecca E. Moore, Steven D. Townsend, Jennifer A. Gaddy, David M. Aronoff
    Clinical Therapeutics.2021; 43(2): 265.     CrossRef
  • Targeting the G protein-coupled estrogen receptor (GPER) in obesity and diabetes
    Geetanjali Sharma, Eric R. Prossnitz
    Endocrine and Metabolic Science.2021; 2: 100080.     CrossRef
  • Changes in Body Composition Are Associated with Metabolic Changes and the Risk of Metabolic Syndrome
    Yun Hwan Oh, Seulggie Choi, Gyeongsil Lee, Joung Sik Son, Kyae Hyung Kim, Sang Min Park
    Journal of Clinical Medicine.2021; 10(4): 745.     CrossRef
  • N6-Adenosine Methylation (m6A) RNA Modification: an Emerging Role in Cardiovascular Diseases
    Ye-shi Chen, Xin-ping Ouyang, Xiao-hua Yu, Petr Novák, Le Zhou, Ping-ping He, Kai Yin
    Journal of Cardiovascular Translational Research.2021; 14(5): 857.     CrossRef
  • From Metabolic Syndrome to Neurological Diseases: Role of Autophagy
    Jessica Maiuolo, Micaela Gliozzi, Vincenzo Musolino, Cristina Carresi, Federica Scarano, Saverio Nucera, Miriam Scicchitano, Francesca Bosco, Stefano Ruga, Maria Caterina Zito, Roberta Macri, Rosamaria Bulotta, Carolina Muscoli, Vincenzo Mollace
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Absent Exercise-Induced Improvements in Fat Oxidation in Women With Polycystic Ovary Syndrome After High-Intensity Interval Training
    Sofie Lionett, Ida Almenning Kiel, Ragnhild Røsbjørgen, Stian Lydersen, Steen Larsen, Trine Moholdt
    Frontiers in Physiology.2021;[Epub]     CrossRef
  • Roles of interstitial fluid pH and weak organic acids in development and amelioration of insulin resistance
    Yoshinori Marunaka
    Biochemical Society Transactions.2021; 49(2): 715.     CrossRef
  • The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: an Updated Overview
    Dimitrios Tsilingiris, Evangelia Tzeravini, Chrysi Koliaki, Maria Dalamaga, Alexander Kokkinos
    Current Obesity Reports.2021; 10(3): 191.     CrossRef
  • Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity
    Andrea De Lorenzo, Vanessa Estato, Hugo C Castro-Faria-Neto, Eduardo Tibirica
    Journal of Inflammation Research.2021; Volume 14: 2267.     CrossRef
  • Thermogenic Fat: Development, Physiological Function, and Therapeutic Potential
    Bruna B. Brandão, Ankita Poojari, Atefeh Rabiee
    International Journal of Molecular Sciences.2021; 22(11): 5906.     CrossRef
  • Metabolic Syndrome in an Aging Society – Role of Oxidant-Antioxidant Imbalance and Inflammation Markers in Disentangling Atherosclerosis
    Sylwia Dziegielewska-Gesiak
    Clinical Interventions in Aging.2021; Volume 16: 1057.     CrossRef
  • Recruitment and remodeling of peridroplet mitochondria in human adipose tissue
    Rebeca Acín-Perez, Anton Petcherski, Michaela Veliova, Ilan Y. Benador, Essam A. Assali, Georgia Colleluori, Saverio Cinti, Alexandra J. Brownstein, Siyouneh Baghdasarian, Masha J. Livhits, Michael W. Yeh, Karthickeyan Chella Krishnan, Laurent Vergnes, Na
    Redox Biology.2021; 46: 102087.     CrossRef
  • New Insights Into Mitochondrial Dysfunction at Disease Susceptibility Loci in the Development of Type 2 Diabetes
    Hannah Maude, Winston Lau, Nikolas Maniatis, Toby Andrew
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effects of sleeve gastrectomy on bone mass, microstructure of femurs and bone metabolism associated serum factors in obese rats
    Ying Xue, Ran Li, Yong Zhao, Ling Li, Yun Zhou
    BMC Endocrine Disorders.2021;[Epub]     CrossRef
  • The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice
    Nabil Rabhi, Kathleen Desevin, Briana Noel Cortez, Ryan Hekman, Jean Z. Lin, Andrew Emili, Stephen R. Farmer
    Scientific Reports.2021;[Epub]     CrossRef
  • Reliability and variation in mitochondrial respiration in human adipose tissue
    Ronni Eg Sahl, Eva Frederikke Høy Helms, Malte Schmücker, Mathias Flensted-Jensen, Arthur Ingersen, Thomas Morville, Flemming Dela, Jørn Wulff Helge, Steen Larsen
    Adipocyte.2021; 10(1): 605.     CrossRef
  • Inhibition of protein tyrosine phosphatase improves mitochondrial bioenergetics and dynamics, reduces oxidative stress, and enhances adipogenic differentiation potential in metabolically impaired progenitor stem cells
    Katarzyna Kornicka-Garbowska, Lynda Bourebaba, Michael Röcken, Krzysztof Marycz
    Cell Communication and Signaling.2021;[Epub]     CrossRef
  • microRNAs in Human Adipose Tissue Physiology and Dysfunction
    Alina Kurylowicz
    Cells.2021; 10(12): 3342.     CrossRef
  • Aging, obese-insulin resistance, and bone remodeling
    Napatsorn Imerb, Chanisa Thonusin, Nipon Chattipakorn, Siriporn C. Chattipakorn
    Mechanisms of Ageing and Development.2020; 191: 111335.     CrossRef
  • Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
    Federica Zatterale, Michele Longo, Jamal Naderi, Gregory Alexander Raciti, Antonella Desiderio, Claudia Miele, Francesco Beguinot
    Frontiers in Physiology.2020;[Epub]     CrossRef
  • Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases?
    Alexis Diaz-Vegas, Pablo Sanchez-Aguilera, James R Krycer, Pablo E Morales, Matías Monsalves-Alvarez, Mariana Cifuentes, Beverly A Rothermel, Sergio Lavandero
    Endocrine Reviews.2020;[Epub]     CrossRef
  • Inflammatory Signaling and Brown Fat Activity
    Farah Omran, Mark Christian
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Omega-3 fatty acids as regulators of brown/beige adipose tissue: from mechanisms to therapeutic potential
    Marta Fernández-Galilea, Elisa Félix-Soriano, Ignacio Colón-Mesa, Xavier Escoté, Maria J. Moreno-Aliaga
    Journal of Physiology and Biochemistry.2020; 76(2): 251.     CrossRef
  • Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes
    Alina Kuryłowicz, Krzysztof Koźniewski
    Molecules.2020; 25(9): 2224.     CrossRef
  • Obese Adipose Tissue Secretion Induces Inflammation in Preadipocytes: Role of Toll-Like Receptor-4
    Mariana Renovato-Martins, Catharina Moreira-Nunes, Georgia C. Atella, Christina Barja-Fidalgo, João Alfredo de Moraes
    Nutrients.2020; 12(9): 2828.     CrossRef
  • Diabetes and Metabolism Journal in 2020: Good to Great
    In-Kyung Jeong
    Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
  • The Effect of Silibinin on Protein Expression Profile in White Adipose Tissue of Obese Mice
    Fei Wang, Shuchun Chen, Luping Ren, Yichao Wang, Zelin Li, Tiantian Song, He Zhang, Qiwen Yang
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Beneficial Effects of Bariatric Surgery-Induced by Weight Loss on the Proteome of Abdominal Subcutaneous Adipose Tissue
    Bárbara María Varela-Rodríguez, Paula Juiz-Valiña, Luis Varela, Elena Outeiriño-Blanco, Susana Belén Bravo, María Jesús García-Brao, Enrique Mena, José Francisco Noguera, Javier Valero-Gasalla, Fernando Cordido, Susana Sangiao-Alvarellos
    Journal of Clinical Medicine.2020; 9(1): 213.     CrossRef
  • Impact of Skeletal Muscle Mass on Metabolic Health
    Gyuri Kim, Jae Hyeon Kim
    Endocrinology and Metabolism.2020; 35(1): 1.     CrossRef
  • Sea buckthorn (Hippophae rhamnoides L.) oil enhances proliferation, adipocytes differentiation and insulin sensitivity in 3T3-L1 cells
    Ting Zhang, Xuze Qin, Yuxin Cao, Jianxin Zhang, Junxing Zhao
    Food Science and Biotechnology.2020; 29(11): 1511.     CrossRef
  • Adipose tissue secretory profile and cardiometabolic risk in obesity
    Pengcheng Zhang, Daniels Konja, Yu Wang
    Endocrine and Metabolic Science.2020; 1(3-4): 100061.     CrossRef
  • Mitochondrial Dynamics in the Brain Are Associated With Feeding, Glucose Homeostasis, and Whole-Body Metabolism
    Jessica L. Haigh, Lauryn E. New, Beatrice M. Filippi
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Adipogenesis: A Necessary but Harmful Strategy
    Mohammed El Hafidi, Mabel Buelna-Chontal, Fausto Sánchez-Muñoz, Roxana Carbó
    International Journal of Molecular Sciences.2019; 20(15): 3657.     CrossRef
Original Articles
Clinical Diabetes & Therapeutics
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
Diabetes Metab J. 2019;43(4):410-421.   Published online December 27, 2018
DOI: https://doi.org/10.4093/dmj.2018.0070
  • 6,556 View
  • 137 Download
  • 19 Web of Science
  • 19 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit.

Methods

Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed.

Results

Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit (P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects (P<0.0001).

Conclusion

Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations.

Citations

Citations to this article as recorded by  
  • Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials,
    Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
    Journal of Clinical Lipidology.2024;[Epub]     CrossRef
  • A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
    Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
    Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
  • Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
    Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
    Current Problems in Cardiology.2023; 48(8): 101228.     CrossRef
  • Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
    Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
    Journal of Cardiovascular Development and Disease.2023; 10(4): 176.     CrossRef
  • Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
    L. Yu. Khamnueva, L. S. Andreeva
    Problems of Endocrinology.2023; 69(2): 38.     CrossRef
  • Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
    Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • Obesity Pillars Roundtable: Obesity and East Asians
    Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
    Obesity Pillars.2022; 2: 100011.     CrossRef
  • Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
    Nature Reviews Endocrinology.2022; 18(7): 413.     CrossRef
  • Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
    Xiaoling Cai, Linong Ji
    Diabetes Therapy.2021; 12(7): 1861.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
  • Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
    Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110342.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
    Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
    Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456.     CrossRef
  • Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
    Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
    Christopher S. Wilcox
    Hypertension.2020; 75(4): 894.     CrossRef
  • Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
    Diabetes Therapy.2020; 11(9): 2121.     CrossRef
  • 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
    Journal of the Chinese Medical Association.2020; 83(7): 587.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Association of Adiponectin and Hepatic Steatosis in Adults with Normal Transaminase Levels.
Jeong Hyun Mun, Seung Eun Lee, Ji Hyun Ahn, Soon Hyun Shinn
Korean Diabetes J. 2008;32(2):149-156.   Published online April 1, 2008
DOI: https://doi.org/10.4093/kdj.2008.32.2.149
  • 2,017 View
  • 20 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome including insulin resistance, hypertension, dyslipidemia, central obesity, type 2 diabetes, and cardiovascular disease. In NAFLD, insulin resistance plays an important role in the progression of liver damage. In this study, we evaluated insulin resistance, plasma adiponectin, hepatic steatosis, and their association in adults with normal liver transaminase concentrations. METHODS: We analyzed 111 subjects, aged over 20 years old, who visited the Health Management Center at Chung-Ang University Hospital between May 2006 and August 2006. They had neither history nor clinical evidence of diabetes, cardiovascular or liver disease. They were divided into three groups by the degree of hepatic steatosis based on ultrasound findings. Anthropometric parameters were measured and blood samples were drawn after eight hours of fasting. RESULTS: Hepatic steatosis had a positive correlation with body mass index, waist circumference, blood pressure, triglycerides, HOMA-IR, and QUICKI. Moreover, it had a negative correlation with high-density lipoprotein cholesterol and adiponectin. Triglycerides, Adiponectin, and QUICKI were independent variables in predicting the degree of hepatic steatosis. CONCLUSION: This finding suggests that triglycerides and plasma adiponectin are independent predictors of hepatic steatosis in adults with normal liver transaminase concentrations.

Citations

Citations to this article as recorded by  
  • Analysis of Biochemical Markers Related to Fatty Liver Patients
    Jae-Hwan Cho, Jang-Sun Namgung, Jin Lee, Deog-Hwan Moon, Hae-Kag Lee
    Journal of Physical Therapy Science.2014; 26(12): 1865.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal